The group's principal activity is to develop human cell therapy for a broad range of medical applications. the group has three product areas in various stages of development: tissue repair cells; Therapeutic cells for immunotherapy; And devices for cell production. the tissue repair cell products under development include the sc-i and cb-i cells for use in stem cell therapy and the oc cell products for the restoration of bone tissue. the lead device products under development include the aastromreplicelltm system and the dc-i and dcv-i kits for the clinical-scale production of dendritic cells intended for the emerging cancer vaccine market. the aastromreplicelltm system is used by the group to produce its proprietary tissue repair and therapeutic cell products and to be sold as an independent product.